Siemens Healthineers Wins RBC Upgrade on Accela Launch as Ultrasound Exit Reshapes Portfolio
Published on 10/16/2026 at 15:31 | Editorial boerse-global.de
Siemens Healthineers shares drew fresh analyst support at the close of the trading week, with RBC Capital Markets lifting its price target on the medical technology group from EUR 45 to EUR 48 while keeping an "Outperform" rating. Investors took the note in stride: the stock added 1.7% to EUR 41.52, building on the prior session's close of EUR 40.81.
At the heart of RBC's more constructive view is Accela, the company's new radiotherapy system. Analyst Natalia Webster argues the platform showcases Siemens Healthineers' core clinical strengths and carries meaningful upside for the business, framing the technological step-up as a clear catalyst for future growth.
That bullish call stands in contrast to the more measured tone elsewhere on the Street. ODDO BHF trimmed its target from EUR 47 to EUR 45 on October 12, though it too retained an "Outperform" rating — a signal that while upside is still seen, near-term expectations have been tempered by the company's ongoing restructuring.
A Deliberate Retreat from Mainstream Ultrasound
The upgrade lands against the backdrop of a broader strategic reset. Siemens Healthineers has discontinued sales of general ultrasound systems, steering the division instead toward interventional imaging, image-guided therapies, and software and artificial intelligence. The affected lines are the Acuson Sequoia, Redwood, Juniper, and Maple models, with service for existing customers continuing uninterrupted.
According to Reuters, the pullback was driven by fierce competition in the standard segment. The ultrasound unit generated just over EUR 600 million in revenue in 2025, equal to 9% of sales in the Precision Therapy division. The company was not a leading player in conventional devices, making it increasingly uneconomical to defend market share there.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Management's aim is to redeploy resources into higher-margin areas. Interventional procedures and image-guided therapies promise richer contribution margins, but they also demand sustained innovation and specialized sales structures — a higher bar than the volume business they replace.
Buyback and Balance Sheet in Focus
The repositioning is being accompanied by an ongoing share repurchase program. Between September 28 and October 4, the group bought back just under 50,000 of its own shares — 49,987 to be precise. Since the program began on June 1, the cumulative volume had reached more than 3.4 million shares by October 4.
The market currently values the company at a market capitalization of EUR 42.82 billion. Stripping out low-margin volume business marks an attempt to shift capital into more profitable niches, though the central question for investors remains whether the retreat lifts operating profitability fast enough to offset the lost revenue.
The Bull and Bear Cases
In the optimistic scenario, concentrating on clinically demanding applications pays off quickly. If Siemens Healthineers can channel freed-up capacity entirely into interventional procedures, it strengthens its position in technology-intensive interventions. Image-guided therapies are viewed as a growth field in modern hospitals as minimally invasive techniques gain ground worldwide, and pairing high-margin system sales with long-term service contracts could lift adjusted earnings.
The risk cuts the other way. The strategic gap in the product lineup could weigh more heavily than anticipated. If customers prefer full-range solutions and defect to broad-line suppliers over the loss of standard devices, adjacent business areas could come under pressure. Every exit from established markets also carries the risk of one-off costs for restructuring and sales adjustments. Should the hoped-for margin gain fail to materialize or the ramp-up of interventional systems stall, the stock could surrender its recent floor.
Chart Levels and the November 5 Test
On the technical front, the shares are trading at EUR 41.01 and holding above their 200-day moving average of EUR 38.07. As long as that closely watched trendline is defended, the broader recovery picture stays intact; a sustained break below it would risk extending the consolidation and retesting lower support levels.
Clarity on the actual business trajectory arrives in a matter of weeks. On November 5, 2026, Siemens Healthineers will publish its fourth-quarter results and preliminary figures for the full 2026 fiscal year at 7 a.m., followed by a balance sheet press conference at 10 a.m. and an analyst conference call. That release will show how resilient the group's profitability truly is — and whether the ultrasound overhaul can underpin expectations for the coming year.
Ad
Siemens Healthineers Stock: New Analysis - 16 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
